scholarly journals Clinical study on gefitinib combined with γ-ray stereotactic body radiation therapy as the first-line treatment regimen for senile patients with adenocarcinoma of the lung (final results of JLY20080085)

2013 ◽  
Vol 1 (4) ◽  
pp. 711-715 ◽  
Author(s):  
DEJIAN PAN ◽  
BIAO WANG ◽  
XIJIAN ZHOU ◽  
DONGLIN WANG
Keyword(s):  
Radiation Therapy ◽  
Clinical Study ◽  
Treatment Regimen ◽  
Stereotactic Body Radiation Therapy ◽  
Line Treatment ◽  
First Line ◽  
Stereotactic Body Radiation ◽  
Adenocarcinoma Of The Lung ◽  
Γ Ray ◽  
First Line Treatment

ABVD and Radiation Therapy as First-Line Treatment in Advanced Hodgkin's Disease

1999 ◽  
Vol 32 (5-6) ◽  
pp. 553-559 ◽  
Author(s):  
P. L. Zinzani ◽  
M. Magagnoli ◽  
G. Frezza ◽  
E. Barbieri ◽  
F. Gherlinzoni ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Line Treatment ◽  
First Line ◽  
Advanced Hodgkin’S Disease ◽  
First Line Treatment

scholarly journals High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis

2020 ◽  
Vol 201 (12) ◽  
pp. 1578-1579 ◽  
Author(s):  
Tom Decroo ◽  
Bouke C. de Jong ◽  
Alberto Piubello ◽  
Mahamadou Bassirou Souleymane ◽  
Lutgarde Lynen ◽  
...  
Keyword(s):  
Treatment Regimen ◽  
High Dose ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Phase II trial of radiation therapy/temozolomide followed by temozolomide/sorafenib in the first-line treatment of glioblastoma multiforme (GBM)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 2018-2018
Author(s):  
R. E. Lamar ◽  
D. R. Spigel ◽  
H. A. Burris ◽  
T. M. Markus ◽  
M. Kuzur ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Line Treatment ◽  
First Line ◽  
Complete Surgical Resection ◽  
Adequate Organ Function ◽  
Grade 3 ◽  
X 24 ◽  
Ecog Ps ◽  
First Line Treatment

2018 Background: Anti-angiogenesis agents have recently shown activity in the treatment of patients (pts) with GBM. We added sorafenib, a multi-targeted TKI, to the standard first-line treatment of patients with GBM. Methods: Pts with histologically documented GBM were eligible at diagnosis or after resection. Additional entry criteria: ECOG PS 0 or 1; adequate organ function; ability to swallow pills; standard exclusions for antiangiogenesis agents. All pts initially received radiation therapy (total 60 Gy, 2 Gy by single daily fractions) plus temozolomide (75mg/m2 po daily). Four weeks after completion of radiation therapy, pts received temozolomide (150mg/m2 po days 1–5, repeated every 21 days for 6 cycles) plus sorafenib (400mg po bid daily x 24 weeks). Pts were evaluated every 8 weeks during temozolomide/sorafenib therapy, and every 3 months after therapy ended, until tumor progression. Median PFS was the primary endpoint. Results: Between April 2007 and July 2008, 45 pts were enrolled. The median age was 54 years; 30 pts (67%) had previous partial or complete surgical resection. 39 pts (87%) completed concurrent RT/temozolomide therapy, while 6 pts were removed from treatment (PD 4, toxicity 1, intercurrent event 1). 39 pts began treatment with temozolomide/sorafenib; 3 have completed all planned treatment, 8 remain on treatment, and 28 stopped treatment early (PD 22, toxicity 2, intercurrent event 1, pt decision 3). Best responses are as follows: CR, 1 pt (2%); PR, 5 pts (11%); stable disease, 22 pts (49%); progressive disease, 14 pts (31%). After a median follow-up of 9 months, median PFS for all pts was 6 months (95% confidence intervals, 2.7–7.8 months). Median PFS for pts who received at least 1 dose of sorafenib is also 6 months. The median overall survival is 16 months (95% CI, 7.2-NR months). Grade 3/4 toxicity during temozolomide/sorafenib was uncommon; 7 pts (16%) required dose reductions of sorafenib during their treatment course. Conclusions: The addition of sorafenib to standard treatment with RT/temozolomide is feasible and well tolerated by most pts. Preliminary efficacy is similar to standard therapy; updated results will be presented. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document